Latest podcasts: American Society of Tropical Medcine and Hygiene, Washington DC; American Heart Association, Orlando
Cardiovascular
Could “Polypill” Massively Reduce Heart, Stroke Risks In Healthy People?
Salim Yusuf
Salim Yusuf, McMaster University, Hamilton
Peter Goodwin interviews Salim Yusuf, McMaster University, Hamilton.
Peter Goodwin interviews Salim Yusuf, McMaster University, Hamilton.
Optimized Anti-Platelet Therapy Avoids Stent Thrombosis With Drug Eluting Stents: HORIZON-AMI Trial Results
George Dangas
George Dangas, Columbia University, New York
Peter Goodwin interviews George Dangas, Columbia University, New York.
Peter Goodwin interviews George Dangas, Columbia University, New York.
American College of Cardiology, Orlando
The 2009 ACC scientific session began with a bang together with the i2 meeting on Saturday March 28th in Orlando, Florida. Peter Goodwin interviewed leading investigators to hear the latest on interventional cardiology, surgery and medical therapy for patients with hypertension, acute coronary syndromes, myocardial infarction, and heart failure.
LDL-How Low?
Terje Pedersen
Terje Pedersen, Ulleval University, Oslo
Eugene Braunwald, Harvard University, Boston
Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no benefit in the SEAS (Simvastatin and Ezetimibe In Aortic Stenosis) study reported by Terje Pederson at a Hot Line session of the E.S.C. Congress. But the potential gains from such lowering in other clinical situations could be considerable, according to Eugene Braunwald who chaired the session. In Munich they talked with Peter Goodwin.
Eugene Braunwald, Harvard University, Boston
Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no benefit in the SEAS (Simvastatin and Ezetimibe In Aortic Stenosis) study reported by Terje Pederson at a Hot Line session of the E.S.C. Congress. But the potential gains from such lowering in other clinical situations could be considerable, according to Eugene Braunwald who chaired the session. In Munich they talked with Peter Goodwin.
For video news reports by Peter Goodwin from the 2008 ESC Congress in Munich, click here.
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick
Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing death, MI or urgent revascularisation in the 4,500-patient ISAR-REACT 3 study presented at the ACC annual meeting. Tony Gershlick and Adnan Kastrati discuss the study with Peter Goodwin and Sara Freeman.
Adnan Kastrati, Deutsches Herzzentrum, Munich
Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing death, MI or urgent revascularisation in the 4,500-patient ISAR-REACT 3 study presented at the ACC annual meeting. Tony Gershlick and Adnan Kastrati discuss the study with Peter Goodwin and Sara Freeman.
Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra
Felix Zijlstra, University Medical Center Groningen, The Netherlands
Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits, according to data from the 1000-patient TAPAS study presented at the ACC meeting. Senior investigator Felix Zijlstra told Sara Freeman about the potentially practice-changing findings.
Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits, according to data from the 1000-patient TAPAS study presented at the ACC meeting. Senior investigator Felix Zijlstra told Sara Freeman about the potentially practice-changing findings.
Heart Failure Drug Prevents Renal Damage?
Barry Massie
Barry Massie, San Francisco VA Medical Center
COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit
The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment and improve acute heart failure symptoms. Barry Massie and Aaron Kugelmass discussed findings from the 300-patient PROTECT pilot study with Sara Freeman.
COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit
The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment and improve acute heart failure symptoms. Barry Massie and Aaron Kugelmass discussed findings from the 300-patient PROTECT pilot study with Sara Freeman.
Never Too Old For Hypertension Treatment!
Nigel Beckett
Nick Boon
Nigel Beckett, Imperial College, London
COMMENT: Nick Boon, British Cardiovascular Society, London
Even very old patients benefit greatly if you treat their hypertension. This is the finding of the randomized HYVET study of 4,000 patients with average age 83. Peter Goodwin talked with investigator Nigel Beckett, who presented details at one of the ACC sessions, and from the chairperson and British Cardiovascular Society President, Nick Boon who added his comments.
COMMENT: Nick Boon, British Cardiovascular Society, London
Even very old patients benefit greatly if you treat their hypertension. This is the finding of the randomized HYVET study of 4,000 patients with average age 83. Peter Goodwin talked with investigator Nigel Beckett, who presented details at one of the ACC sessions, and from the chairperson and British Cardiovascular Society President, Nick Boon who added his comments.
Routine Angioplasty Recommended After Thrombolysis
Warren Cantor
Tony Gershlick
REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction
Warren Cantor, University of Toronto
COMMENT: Tony Gershlick, Leicester University
A new study has shown important gains from adding angioplasty routinely to therapy for all patients receiving thrombolysis for acute myocardial infarction if it is available within 6 hours. This comes from the 1 000-patient TRANSFER-AMI study which Warren Cantor presented to the ACC. He talked with Peter Goodwin who also discussed the findings with Tony Gershlick.
Warren Cantor, University of Toronto
COMMENT: Tony Gershlick, Leicester University
A new study has shown important gains from adding angioplasty routinely to therapy for all patients receiving thrombolysis for acute myocardial infarction if it is available within 6 hours. This comes from the 1 000-patient TRANSFER-AMI study which Warren Cantor presented to the ACC. He talked with Peter Goodwin who also discussed the findings with Tony Gershlick.
Protective Cardiovascular Benefit for Women on HRT For Natural Menopause
George Sopko
REFERENCE: Abstract 3771, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
GEORGE SOPKO, National Heart, Lung And Blood Institute, Bethesda, Maryland
COMMENT: JENNIFER MIERES, New York University
A new study presented to the American Heart Association meeting found women taking hormone replacement therapy since the menopause had a protective cardiovascular benefit. This was greater the earlier HRT was initiated and the women who took HRT had lower rates of coronary artery disease. Chief study author George Sopko spoke with Sarah Maxwell at the Orlando meeting.
N Engl J Med 2007;357
GEORGE SOPKO, National Heart, Lung And Blood Institute, Bethesda, Maryland
COMMENT: JENNIFER MIERES, New York University
A new study presented to the American Heart Association meeting found women taking hormone replacement therapy since the menopause had a protective cardiovascular benefit. This was greater the earlier HRT was initiated and the women who took HRT had lower rates of coronary artery disease. Chief study author George Sopko spoke with Sarah Maxwell at the Orlando meeting.
Oral Contraceptive Use: More Carotid and Femoral Atheroschlerosis Later in Life
Ernst Rietzschel
Jennifer Mieres
REFERENCE: News Briefing, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
ERNST RIETZSCHEL, University of Ghent, Belgium
COMMENT: JENNIFER MIERES, New York University
Women who used the contraceptive pill had increases in atherosclerotic plaque in their carotid and femoral arteries of between 20 and 30 percent by the time they reached late middle age. This is the finding of the ASKLEPIOS study conducted by the University of Ghent in which plaque was measured by ultrasound in 2 500 healthy men and women. Ernst Rietzschel presented data from the study to the 2007 Sessions of the AHA, and afterwards discussed the findings with Peter Goodwin.
N Engl J Med 2007;357
ERNST RIETZSCHEL, University of Ghent, Belgium
COMMENT: JENNIFER MIERES, New York University
Women who used the contraceptive pill had increases in atherosclerotic plaque in their carotid and femoral arteries of between 20 and 30 percent by the time they reached late middle age. This is the finding of the ASKLEPIOS study conducted by the University of Ghent in which plaque was measured by ultrasound in 2 500 healthy men and women. Ernst Rietzschel presented data from the study to the 2007 Sessions of the AHA, and afterwards discussed the findings with Peter Goodwin.
TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?
Gregg Stone
REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone presented data from the TAXUS DES trials which looked at patients surviving more than a year after receiving either paclitaxel-eluting or bare metal stents. After his talk at the American Heart Association he discussed his findings with Sarah Maxwell.
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone presented data from the TAXUS DES trials which looked at patients surviving more than a year after receiving either paclitaxel-eluting or bare metal stents. After his talk at the American Heart Association he discussed his findings with Sarah Maxwell.
© 2007 Audio Medica – Medical Audio News Interviews & Podcasts. 
